Isolation of efficient antivirals: Genetic suppressor elements against HIV-1

Gene Therapy

Volumn 6, Issue 1, 1999, Pages 130-137

  Dunn, S J ^a,b   Park, S W ^a   Sharma, V ^a,b   Raghu, G ^a   Simone, J M ^a,b   Tavassoli, R ^a,b   Young, L M ^a,b   Ortega, M A ^a,b   Pan, C H ^a,b   Alegre, G J ^a,b   Roninson, I B ^c   Lipkina, G ^a,b   Dayn, A ^a   Holzmayer, T A ^a,b  

^a Ingenex Inc   (United States)

^b Pharmaceutical Product Development   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Flow cytometry; Genetic suppressor elements; HIV

Indexed keywords

CELL ANTIGEN; MEMBRANE ANTIGEN; VIRUS VECTOR;

ARTICLE; FLOW CYTOMETRY; GENE REPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS GENOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIVIRAL AGENTS; FLOW CYTOMETRY; GENE LIBRARY; GENE THERAPY; GENES, SUPPRESSOR; GENOME, VIRAL; HIV-1; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 6544276460     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300791     Document Type: Article

References (37)

1. Holzmayer TA, Pestov DG, Roninson IB. Isolation of dominant negative mutants and inhibitory antisense RNA sequences by expression selection of random DNA fragments. Nucleic Acids Res 1992; 20: 711-717.
2. Gudkov AV et al. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci USA 1993; 90: 3231-3235.
3. Gudkov AV et al. Cloning mammalian genes by expression selection of genetic suppressor elements: association of kinesin with drug resistance and immortalization. Proc Natl Acad Sci USA 1994; 91: 3744-3748.
4. Pestov DG, Lau L. Genetic selection of growth-inhibitory sequences in mammalian cells. Proc Natl Acad Sci USA 1994; 91: 12549-12553.
5. Ossovskaya VS et al. Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. Proc Natl Acad Sci USA 1996; 93: 10309-10314.
6. INGI promotes neoplastic transformation. Nat Genet 1996; 14: 415-420.
7. Gallagher WM et al. Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene 1997; 14: 185-193.
8. Tenson T, DeBlasio A, Mankin A. A functional peptide encoded in the Escherichia coli 23 rRNA. Proc Natl Acad Sci USA 1996; 93: 5641-5646.
9. Sanford JC. Applying the PDR principle to AIDS. J Theor Biol 1988; 130: 469-480.
10. Baltimore D. Intracellular immunization Nature 1988; 335 395-396.
11. Gilboa E, Smith C. Gene therapy for infectious diseases, the AIDS model. Trends Genet 1994; 10: 139-144
12. Yu M, Poeschla E, Wong-Staal F. Progress towards gene therapy for HIV infection. Gene Therapy 1994; 1: 13-26.
13. Dropulic B, Jeang K-T. Gene therapy for human immunodeficiency virus infection: genetic antiviral strategies and targets for intervention. Hum Gene Ther 1994; 5: 927-939.
14. Junker U et al. Intracellular expression of human immunodeficiency virus type 1 (HIV-1) protease variants inhibits replication of wild-type and protease inhibitor-resistant HIV-1 strains in human T cell lines. J Virol 1996; 70: 7765-7772.
15. + cell model of chronic infection. J Virol 1991; 65 4645-4653.
16. Coffin JM. HIV population dynamics in vivo implications for genetic variation, pathogenesis and therapy. Science 1995; 267 483-489.
17. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69: 5087-5094.
18. Malim MH et al. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med 1992; 176: 1197-1201.
19. Bevec D, Dobrovnik M, Hauber J, Bohnlein E. Inhibition of human immunodeficiency virus type 1 replication in human T cells by retrovirus-mediated gene transfer of a dominant-negative rev trans-activator. Proc Natl Acad Sci USA 1992; 89: 9870-9874.
20. Woffendin C et al. Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. Proc Natl Acad Sci USA 1994; 91: 11581-11585.
21. Malim MH, Bohnlein S, Hauber J, Cullen BR. Functional dissection of the HIV-1 Rev trans-activator: derivation of a trans-dominant repressor of Rev function. Cell 1989; 58: 205-214.
22. Pearson L et al. A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci USA 1990; 87: 5079-5083.
23. Bahner I et al. Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J Virol 1993; 67: 3199-3207.
24. Caputo A et al. Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication. Gene Therapy 1997; 4: 288-295.
25. Vandendrissche T et al. Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary T lymphocytes by retroviral vectors expressing anti-HIV genes. J Virol 1995; 69: 4045-4052.
26. Lui J, Woffendin C, Yang Z, Nabel GJ. Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells. Gene Therapy 1994; 1: 32-37.
27. Chua MKL et al. Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense TAR. Hum Gene Ther 1994; 5: 3467-1475.
28. Plavec I et al. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. Gene Therapy 1997; 4: 128-139.
29. Lee S-W, Gallardo HF, Gilboa E, Smith C. Inhibition of human immunodeficiency virus type 1 in human T cells by potent Rev response element decoy consisting of the 13-nudeotide minimal repeat Rev-binding domain. J Virol 1994; 68: 8254-8264.
30. Ulich C, Harrick D, Estes P, Gaynor RB. Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev J Virol 1996; 70: 4871-4876.
31. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. BioTechniques 1989; 7: 980-990.
32. Gendelman HE et al. Traris-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci USA 1986; 83: 9759-9763.
33. Fisher AG et al. A molecular clone of HTLV-III with biological activity. Nature 1985; 316: 262-265.
34. Gudkov AV, Roninson IB. Isolation of genetic suppressor elements (GSEs) from random fragment cDNA libraries in retroviral vectors. In: Cowell IG, Austin CA (eds). Methods in Molecular Biology, vol 69: cDNA Protocols. Humana Press: Totowa, NJ, 1996, pp 221-340.
35. Johnson VA, Byington RE. Quantitative assays for virus infectivity. In: Aldovini A, Walker BD (eds). Techniques in HIV Research. Stockton Press: New York, 1990, pp 71-86.
36. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning, a Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 1989.
37. Gadol N, Crutcher G, Busch MP. Detection of intracellular HIV in lymphocytes by flow cytometry. Cytometry 1994; 15: 359-370.